首页|免疫组化在肺活检小细胞肺癌与非小细胞肺癌中的应用

免疫组化在肺活检小细胞肺癌与非小细胞肺癌中的应用

扫码查看
目的 以病理学诊断为标准,分析免疫组化法在鉴别肺活检小细胞肺癌与非小细胞肺癌过程中多种分子标记物的表达来确定肺癌类型。方法 分析 13 例小细胞肺癌和 47 例非小细胞肺癌患者的肺穿刺活检标本、纤维支气管镜活检标本和病理资料,采用免疫组化法检测病理样本组织中CK、CK7、Napsin A、P40、P63、CgA、Syn、CD56、TTF-1、Ki-67 等多种分子标记物表达水平。比较非小细胞肺癌与小细胞肺癌患者的肺癌分子标记物阳性表达率,分析肺癌分子标记物在小细胞肺癌(CgA、Syn、CD56、Ki-67)及非小细胞肺癌(P40、P63、Napsin A)中的诊断效能。结果 小细胞肺癌患者的CgA、Syn、CD56、Ki-67、TTF-1 阳性表达率分别为 92。3%、92。3%、100。0%、92。3%、92。3%,均高于非小细胞肺癌患者的 4。2%、2。1%、4。2%、6。4%、34。0%,P40、P63、Napsin A阳性表达率分别为 0、0、0,均低于非小细胞肺癌患者的 59。6%、55。3%、25。5%,有显著差异(P<0。05);非小细胞肺癌与小细胞肺癌患者的CK7 阳性表达率差异无统计学意义(P>0。05)。非小细胞肺癌与小细胞肺癌患者的CK阳性表达率均为 100。0%。CgA、Syn、CD56、Ki-67 诊断小细胞肺癌的敏感性分别为 0。923、0。923、1。000、0。923,特异性分别为 0。957、0。979、0。957、0。936,准确率分别为 0。950、0。967、0。967、0。933。P63、P40 和Napsin A在非小细胞肺癌中呈现高阳性率,P40、P63 和Napsin A诊断非小细胞肺癌的敏感性分别为0。596、0。553、0。255,特异性分别为 1。000、1。000、1。000,准确率分别为 0。683、0。650、0。417。结论 病理学诊断结合免疫组化检测P63、P40和Napsin A的表达水平在非小细胞肺癌诊断中具有较高的可靠性;而病理学诊断结合免疫组化检测CgA、Syn、CD56 和Ki-67 的表达水平在小细胞肺癌诊断中具有较高的可靠性,免疫组化检测可为小细胞肺癌和非小细胞肺癌的病理学诊断提供参考依据,值得临床推广应用。
Application of immunohistochemistry in lung biopsy of small cell lung cancer and non-small cell lung cancer
Objective Based on the pathological diagnosis,the expression of multiple molecular markers by immunohistochemistry in differentiating small cell lung cancer from non-small cell lung cancer on lung biopsy.Methods Lung puncture biopsy specimens,fiberoptic bronchoscopy biopsy specimens and pathological data of 13 small cell lung cancer and 47 non-small cell lung cancer patients were analyzed,and the expression levels of multiple molecular markers such as CK,CK7,Napsin A,P40,P63,CgA,Syn,CD56,TTF-1,and Ki-67 were detected in tissues of pathological specimens by immunohistochemistry.The positive expression rates of lung cancer molecular markers were compared between patients with non-small cell lung cancer and small cell lung cancer,and the diagnostic efficacy of lung cancer molecular markers in small cell lung cancer(CgA,Syn,CD56,Ki-67)and non-small cell lung cancer(P40,P63,Napsin A)was analyzed.Results The positive expression rates of CgA,Syn,CD56,Ki-67 and TTF-1 in small cell lung cancer patients were 92.3%,92.3%,100.0%,92.3%and 92.3%,which were higher than 4.2%,2.1%,4.2%,6.4%and 34.0%in non-small cell lung cancer patients;the positive expression rates of P40,P63 and Napsin A in small cell lung cancer patients were 0,0 and 0,which were lower than 59.6%,55.3%and 25.5%in non-small cell lung cancer patients;there were significant differences(P<0.05).The difference in CK7 positive expression rate between non-small cell lung cancer patients and small cell lung cancer patients was not statistically significant(P>0.05).The CK positive expression rate of non-small cell lung cancer patients and small cell lung cancer patients was both 100.0%.The sensitivity of CgA,Syn,CD56 and Ki-67 in diagnosing small cell lung cancer was 0.923,0.923,1.000,0.923,the specificity was 0.957,0.979,0.957,0.936,and the accuracy was 0.950,0.967,0.967,0.933.P63,P40 and Napsin A showed high positivity in non-small cell lung cancer.The sensitivity of P40,P63 and Napsin A in the diagnosis of non-small cell lung cancer was 0.596,0.553 and 0.255,and the specificity was 1.000,1.000 and 1.000,and the accuracy was 0.683,0.650 and 0.417.Conclusion Pathological diagnosis combined with immunohistochemistry to detect the expression levels of P63,P40 and Napsin A has high reliability in the diagnosis of non-small cell lung cancer;while pathological diagnosis combined with immunohistochemistry to detect the expression levels of CgA,Syn,CD56 and Ki-67 has high reliability in the diagnosis of small cell lung cancer.Immunohistochemical detection can provide a reference basis for the pathological diagnosis of both small cell lung cancer and non-small cell lung cancer,and is worthy of clinical promotion and application.

Small cell lung cancerNon-small cell lung cancerImmunohistochemistryLung biopsy

张伟基

展开 >

333000 景德镇市第一人民医院病理科

小细胞肺癌 非小细胞肺癌 免疫组化 肺活检

景德镇市科技计划

20202SFZC033

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(5)
  • 16